Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06934408
PHASE1

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single and multiple doses in adults who are affected by obesity.

Official title: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Injections of HRS-5817 Injection in Healthy Adult Volunteers With or Without Obesity

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

92

Start Date

2025-05-08

Completion Date

2027-04

Last Updated

2025-11-17

Healthy Volunteers

Yes

Interventions

DRUG

HRS-5817 Injection

HRS-5817 injection administered subcutaneously (SC).

DRUG

HRS-5817 Injection Placebo

HRS-5817 injection placebo administered subcutaneously (SC).

Locations (1)

The Second Hospital of Anhui Medical Uniersity

Hefei, Anhui, China